Industry
Biotechnology companies
VCMC tracks 10,165 companies in Biotechnology. 1,557 of them have raised a venture or growth round, $90.30B in total, with a median round of $18M; 756 raised since 2024. 1,530 of the 1,557 have a VCMC valuation; the median is $84.2M.
10,165
companies tracked
1,557
venture-backed
15% of those tracked
$90.30B
raised in total
by 1,472 companies
$18M
median round
of 2,084 rounds with an amount
$84.2M
median valuation
of 1,530 companies valued
Values cover private companies only; public companies are not included.
By their latest round, most are at Series A (508 of 1,557).
- Pre-seed 76
- Seed 467
- Series A 508
- Series B 251
- Series C and later 242
- Stage not stated 13
The companies
Biotechnology companies
The 50 venture-backed companies below are this page's list; Flagship Pioneering has raised the most ($3.60B).
| # | Last round | History | Range | Trend | Grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Flagship Pioneering Cambridge, United States | Growth Equity Jul 2024 $3.60B | $45.6B | $16.1B – $69.4B | $29.0B (-36%) | $4.1B | 0% | 821 | up | C | |
| 2 | Isomorphic Labs London, United Kingdom | Series B May 2026 $2.10B | $15.2B | $9.1B – $27.4B | $19.3B (+27%) | $2.3B | 0% | 432 | growing | B | |
| 3 | Retro Bio Redwood City, United States | Series A Jan 2025 $1.00B | $10.0B | $5.4B – $11.5B | $10.0B (0%) | $1.4B | 0% | 99 | growing | B | |
| 4 | Xaira Therapeutics South San Francisco, United States | Growth Equity Apr 2024 $1.00B | $15.2B | $4.9B – $23.1B | $9.1B (-40%) | $1.4B | 0% | 212 | up | C | |
| 5 | Element Biosciences San Diego, United States | Series E Jun 2026 $175M | $2.4B | $1.4B – $4.4B | $2.9B (+18%) | $315M | 0% | 448 | flat | B | |
| 6 | Altos Labs Redwood City, United States | Series B Jan 2022 $800M | $3.4B | $371M – $7.4B | $3.1B (-7%) | $928M | 23% | 549 | flat | D | |
| 7 | Inari Cambridge, United States | Growth Equity Jan 2025 $144M | $1.4B | $738M – $2.5B | $1.0B (-26%) | $167M | 71% | 495 | down | C | |
| 8 | Enveda Boulder, United States | Series E Sep 2026 $311M | $2.0B | $1.7B – $3.0B | $2.6B (+27%) | $286M | 0% | 381 | up | A | |
| 9 | Mirador San Diego, United States | Series B Sep 2025 $250M | $2.8B | $1.2B – $4.3B | $2.8B (0%) | $307M | 0% | 97 | up | C | |
| 10 | NewLimit South San Francisco, United States | Series C Jun 2026 $435M | $3.5B | $2.7B – $4.9B | $4.2B (+21%) | $464M | 0% | 64 | growing | A | |
| 11 | Arsenal Bio South San Francisco, United States | Series C Sep 2024 $325M | $1.6B | $918M – $3.4B | $826M (-47%) | $368M | 97% | 168 | shrinking | C | |
| 12 | LifeMine Cambridge, United States | Series E Aug 2026 $263M | $2.0B | $1.4B – $2.9B | $1.9B (-8%) | $288M | 97% | 32 | shrinking | B | |
| 13 | Ultima Genomics Fremont, United States | Growth Equity Jun 2022 $600M | $3.8B | $419M – $10.1B | $3.7B (-3%) | $660M | 18% | 307 | flat | D | |
| 14 | Kriya Therapeutics Morrisville, United States | Series D Sep 2025 $320M | $4.7B | $2.4B – $7.3B | $4.3B (-8%) | $566M | 28% | 194 | flat | B | |
| 15 | Tessera Therapeutics Somerville, United States | Grant Oct 2025 $41M | $420M | $206M – $1.8B | $361M (-14%) | $437M | 97% | 210 | shrinking | D | |
| 16 | insitro South San Francisco, United States | Series C Mar 2021 $400M | $1.1B | $195M – $5.8B | $1.0B (-10%) | $497M | 59% | 257 | flat | D | |
| 17 | Encoded Therapeutics South San Francisco, United States | Series F Sep 2026 $275M | $3.6B | $2.3B – $6.8B | $4.5B (+26%) | $492M | 0% | 192 | up | B | |
| 18 | Kallyope New York, United States | Series D Feb 2022 $236M | $236M | $93.0M – $1.8B | $223M (-6%) | $169M | 97% | 54 | down | D | |
| 19 | eGenesis Cambridge, United States | Series D Sep 2024 $191M | $3.3B | $1.3B – $5.1B | $2.3B (-30%) | $368M | 0% | 154 | up | C | |
| 20 | Pathos Chicago, United States | Series D May 2025 $365M | $2.1B | $1.3B – $2.5B | $2.1B (0%) | $235M | 0% | 98 | up | B | |
| 21 | Colossal Austin, United States | Series C Jan 2025 $200M | $14.4B | $8.6B – $16.6B | $14.4B (0%) | $1.6B | 0% | 266 | up | B | |
| 22 | Wilmington, United States | Series C May 2021 $200M | $470M | $75.1M – $2.5B | $421M (-10%) | $213M | 54% | 37 | flat | D | |
| 23 | Singapore | Series C May 2021 $125M | $301M | $62.8M – $1.4B | $264M (-12%) | $134M | 53% | 85 | up | D | |
| 24 | Nivelles, Belgium | Acquisition Jun 2023 $149M | $932M acquired 2023 | $203M – $1.3B | – | – | 0% | 88 | flat | C | |
| 25 | Wilmington, United States | Acquisition Mar 2026 $2.00B | $1.1B acquired 2026 | $211M – $1.7B | – | – | 2% | 47 | flat | D | |
| 26 | Mataró, Spain | Series C May 2022 $55M | $246M | $32.1M – $881M | $219M (-11%) | $75.8M | 37% | 32 | flat | D | |
| 27 | Wilmington, United States | Series A Feb 2026 $39M | $391M | $187M – $677M | $477M (+22%) | $66.8M | 0% | 33 | growing | C | |
| 28 | Solna, Sweden | Other Apr 2026 $20M | $261M | $58.2M – $398M | $202M (-23%) | $39.9M | 0% | 65 | up | C | |
| 29 | Peptone Bellinzona, Switzerland | Series A Jun 2022 $40M | $157M | $12.9M – $378M | $144M (-8%) | $46.9M | 20% | 45 | flat | D | |
| 30 | Israel | Other Jun 2026 $8.0M | $41.7M | $6.93M – $191M | $40.7M (-2%) | $19.7M | 58% | 37 | down | D | |
| 31 | Wilmington, United States | Grant Jun 2026 $2.5M | $213M | $96.2M – $349M | $246M (+15%) | $34.4M | 0% | 55 | growing | C | |
| 32 | Gosselies, Belgium | Series A Sep 2023 $29M | $81.5M | $20.9M – $313M | $63.4M (-22%) | $40.4M | 59% | 13 | flat | D | |
| 33 | Palmerston North, New Zealand | Bridge Apr 2025 $8.3M | $85.3M | $7.61M – $162M | $75.6M (-11%) | $16.3M | 16% | 36 | flat | D | |
| 34 | China, Mexico | Series A Aug 2024 $14M | $84.9M | $18.1M – $150M | $46.2M (-46%) | $17.7M | 20% | 6 | unknown | D | |
| 35 | Singapore | Series A Oct 2021 $27M | $119M | $6.38M – $291M | $109M (-8%) | $37.8M | 10% | 18 | flat | D | |
| 36 | Canberra, Australia | Series B Jun 2024 $18M | $507M | $316M – $583M | $349M (-31%) | $64.1M | 0% | 36 | growing | B | |
| 37 | Bergen, Norway | Other Apr 2025 $6.0M | $115M | $8.25M – $262M | $106M (-8%) | $32.6M | 23% | 12 | flat | D | |
| 38 | Angleur, Belgium | Series B Feb 2021 $26M | $33.9M | $6.47M – $176M | $32.8M (-3%) | $20.7M | 70% | 5 | unknown | D | |
| 39 | Gosselies, Belgium | Series A Jun 2021 $24M | $125M | $8.76M – $292M | $118M (-5%) | $33.6M | 2% | 15 | up | D | |
| 40 | Esplugues de Llobregat, Spain | Pre-Seed Sep 2025 $13M | $168M | $55.2M – $257M | $163M (-3%) | $34.6M | 7% | 25 | up | C | |
| 41 | Singapore | Series A May 2024 $15M | $94.0M | $21.2M – $176M | $66.0M (-30%) | $21.1M | 30% | 29 | flat | D | |
| 42 | Singapore | Series A May 2018 $20M | $16.0M | $5.62M – $122M | $16.0M (0%) | $28.0M | 97% | 12 | down | D | |
| 43 | Cerdanyola del Vallès, Spain | Series A Oct 2025 $14M | $128M | $45.5M – $195M | $128M (0%) | $19.6M | 0% | 20 | unknown | C | |
| 44 | Baseimmune London, United Kingdom | Series A Feb 2024 $11M | $112M | $24.1M – $159M | $81.2M (-27%) | $17.1M | 0% | 29 | up | C | |
| 45 | Wilmington, United States | Other Feb 2022 $7.5M | $37.8M | $3.29M – $78.1M | $35.4M (-6%) | $12.6M | 20% | 46 | flat | D | |
| 46 | Diepenbeek, Belgium | Series B Jun 2013 $16M | $154M | $6.76M – $235M | $154M (0%) | $18.5M | 0% | 5 | unknown | D | |
| 47 | Pear Bio Natick, United States | Series A May 2023 $14M | $16.7M | $8.64M – $48.6M | $10.5M (-37%) | $16.1M | 97% | 9 | shrinking | C | |
| 48 | Multiomic Health London, United Kingdom | Seed May 2023 $6.2M | $10.4M | $5.65M – $23.2M | $6.47M (-38%) | $14.9M | 97% | 13 | shrinking | C | |
| 49 | BioCorteX London, United Kingdom | Seed Mar 2023 $5.0M | $9.34M | $3.85M – $47.4M | $6.84M (-27%) | $12.0M | 97% | 13 | down | D | |
| 50 | PentaBind London, United Kingdom | Seed Jun 2025 | $40.7M | $10.4M – $81.1M | $40.7M (0%) | $7.98M | 0% | 15 | growing | D |
Showing 50 of 10,165. Load more lists every other company here, 50 at a time.
Valuations
How these companies are valued
1,530 of the 1,557 venture-backed companies here have a VCMC valuation; the median is $84.2M. A company acquired after its last round keeps its last value as a private company and is left out of the median. 36 companies have disclosed a valuation; for the rest VCMC's valuation is the only number. Each valuation comes with a range, from a low to a high scenario, and a prediction for a year from now. Values cover private companies only; public companies are not included. How VCMC values companies.
Investors
Who backs them
Firms that backed two or more of these companies. Alexandria Venture Investments backed 85, ARCH Venture Partners 59.
- Alexandria Venture Investments 85 companies, led 2
- ARCH Venture Partners 59 companies, led 19
- 53 companies, led 18
- 44 companies, led 17
- 41 companies, led 9
- 36 companies, led 8
- Y Combinator 36 companies, led 5
- Eli Lilly and Company 36 companies, led 2
- GV 33 companies, led 6
- Invus 33 companies
- 32 companies, led 13
- 31 companies, led 5
Recent rounds
Latest funding
278 rounds from Oct 2025 to Sep 2026, $13.23B with a disclosed amount.
- Series C, led by Ligand Pharmaceuticals $41M 24 Sep 2026
- Series C, with DFJ Growth and Premji Invest $75M 24 Sep 2026
- Growth, led by ITOCHU Corporation $14M 24 Sep 2026
- Series C, led by S32 $140M 23 Sep 2026
- Enveda Series E, led by Catalio Capital Management $311M 23 Sep 2026
- Pre-seed, led by Metavallon VC $344K 21 Sep 2026
- Series A, led by LB Investment $10M 18 Sep 2026
- Series A, led by Leaps by Bayer amount not disclosed 17 Sep 2026
- Seed, with Heal Capital and Ananda Impact Ventures $7.4M 15 Sep 2026
- Series A, with Schooner Capital and existing investors $30M 15 Sep 2026
- Seed, led by Eurazeo and Salica Investments $3.5M 13 Sep 2026
- Growth, led by Medicxi $62M 11 Sep 2026
Browse
Related groups
Biotechnology by city
Biotechnology by country
Other industries
Questions
Frequently asked
How many biotechnology companies does VCMC track?
10,165. 1,557 of them have raised a venture or growth round.
How much have biotechnology companies raised?
$90.30B in total across the 1,472 with a known amount; the median round is $18M. 756 raised a round since 2024.
Which biotechnology companies have raised the most?
Flagship Pioneering ($3.60B), Isomorphic Labs ($2.70B), Retro Bio ($1.18B).
Which investors back biotechnology companies most often?
Alexandria Venture Investments (85 companies), ARCH Venture Partners (59 companies), RA Capital (53 companies).
What are biotechnology companies worth?
The median VCMC valuation is $84.2M across 1,530 companies; companies acquired after their last round are left out. Values cover private companies only; public companies are not included.
What was the latest funding round?
AvenCell raised a Series C round of $41M (Sep 2026), led by Ligand Pharmaceuticals.